AU7336400A - Diagnostic assay for type 2 heparin-induced thrombocytopenia - Google Patents

Diagnostic assay for type 2 heparin-induced thrombocytopenia

Info

Publication number
AU7336400A
AU7336400A AU73364/00A AU7336400A AU7336400A AU 7336400 A AU7336400 A AU 7336400A AU 73364/00 A AU73364/00 A AU 73364/00A AU 7336400 A AU7336400 A AU 7336400A AU 7336400 A AU7336400 A AU 7336400A
Authority
AU
Australia
Prior art keywords
heparin
type
induced thrombocytopenia
diagnostic assay
thrombocytopenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU73364/00A
Inventor
Mustapha Abdelouahed
John W Lawler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU7336400A publication Critical patent/AU7336400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders

Abstract

Methods for detecting the presence of antibodies to PF4/heparin/TSP-1 complexes in a biological sample and for diagnosing Type 2 heparin-induced thrombocytopenia are described.
AU73364/00A 1999-08-30 2000-08-29 Diagnostic assay for type 2 heparin-induced thrombocytopenia Abandoned AU7336400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15131499P 1999-08-30 1999-08-30
US60151314 1999-08-30
PCT/US2000/023707 WO2001016184A2 (en) 1999-08-30 2000-08-29 Diagnostic assay for type 2 heparin-induced thrombocytopenia

Publications (1)

Publication Number Publication Date
AU7336400A true AU7336400A (en) 2001-03-26

Family

ID=22538197

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73364/00A Abandoned AU7336400A (en) 1999-08-30 2000-08-29 Diagnostic assay for type 2 heparin-induced thrombocytopenia

Country Status (7)

Country Link
US (1) US7011953B2 (en)
EP (1) EP1254181B1 (en)
AT (1) ATE343597T1 (en)
AU (1) AU7336400A (en)
CA (1) CA2401411A1 (en)
DE (1) DE60031576D1 (en)
WO (1) WO2001016184A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732213B2 (en) * 1999-02-22 2010-06-08 Coramed Healthcare, Inc. Method of evaluating patient hemostasis
US8008086B2 (en) * 1999-02-22 2011-08-30 Cora Healthcare, Inc. Protocol for monitoring direct thrombin inhibition
US7179652B2 (en) * 1999-02-22 2007-02-20 Haemoscope Corporation Protocol for monitoring platelet inhibition
US7655411B2 (en) * 2002-08-23 2010-02-02 W2 Holdings, Inc. Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer
US7524670B2 (en) * 2003-08-05 2009-04-28 Haemoscope Corporation Protocol and apparatus for determining heparin-induced thrombocytopenia
US20060074049A1 (en) * 2004-10-05 2006-04-06 Mitchell Krathwohl Use of heparinoids for treatment and prevention of dementia
FR2902884B1 (en) * 2006-06-23 2008-12-26 Hyphen Biomed Soc Par Actions METHOD FOR DETECTION OF HEPARIN-DEPENDENT ANTIBODIES AND DIAGNOSIS OF HEPARIN-POTENTIATED IMMUNE OR SELF-IMMUNE PATHOLOGIES SUCH AS HEPARIN-INDUCED THROMBOPENIA
US8940495B2 (en) 2008-02-29 2015-01-27 BioMedomics, Inc Rapid and sensitive method for quantitative determination of the level of heparin—PF4 complex induced immunoglobulin antibodies
US9322825B2 (en) * 2008-08-27 2016-04-26 Lsi Medience Corporation Modified anti-heparin/PF4 complex antibody and HIT antibody standard
US10012658B2 (en) * 2011-01-20 2018-07-03 Emosis Platelet analysis system
AU2012268393B2 (en) 2011-06-09 2016-09-15 Gen-Probe Incorporated Diagnostic devices, methods and systems for detecting platelet factor 4 (PF4)/heparin antibodies
EP2828658B1 (en) * 2012-03-23 2017-06-14 The Trustees Of The University Of Pennsylvania Methods of identifying hit-antibodies and pf4 antagonists and cell lines for use therein
WO2013165969A2 (en) * 2012-05-01 2013-11-07 The Trustees Of The University Of Pennsylvania Methods and kits for diagnosing heparin-induced thrombocytopenia
CA3057743A1 (en) * 2017-03-29 2018-10-04 Emosis A rapid, on-demand heparin-induced thrombocytopenia functional assay
CN108956998A (en) * 2018-04-11 2018-12-07 中翰盛泰生物技术股份有限公司 A kind of heparin-binding protein assay kit and measuring method using immunofluorescence dry type quantitative method
CN112255416A (en) * 2020-09-29 2021-01-22 北京利德曼生化股份有限公司 Kit for quantitatively detecting HBP (hepatitis B protein) by using magnetic particle chemiluminescence as well as preparation and detection methods thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5466582A (en) * 1990-08-09 1995-11-14 Serbio Thrombocytopenia determination
US5585243A (en) 1993-09-15 1996-12-17 The Blood Center Of Southeastern Wisconsin, Inc. Method of detecting cytopenia that is mediated by drug-dependent antibody binding to blood cells
US5763201A (en) * 1996-02-05 1998-06-09 Emory University Flow cytometry assay for heparin-induced thrombocytopenia
US5972718A (en) * 1996-02-28 1999-10-26 The Blood Center Research Foundation Method of detecting heparin-induced thrombocytopenia
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

Also Published As

Publication number Publication date
WO2001016184A2 (en) 2001-03-08
ATE343597T1 (en) 2006-11-15
EP1254181A2 (en) 2002-11-06
DE60031576D1 (en) 2006-12-07
CA2401411A1 (en) 2001-03-08
US20020197697A1 (en) 2002-12-26
US7011953B2 (en) 2006-03-14
WO2001016184A3 (en) 2001-06-21
EP1254181B1 (en) 2006-10-25

Similar Documents

Publication Publication Date Title
AU7336400A (en) Diagnostic assay for type 2 heparin-induced thrombocytopenia
CA2249638A1 (en) Kit and method for fluorescence based detection assay
EP1854808A3 (en) Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
DK0749325T3 (en) Bispecific molecules with clinical application
ATE318147T1 (en) SPECIFIC MONOCLONAL ANTIBODIES FOR THE EXTRACELLULAR DOMAIN OF PROTASTA-SPECIFIC MEMBRANE ANTIGEN
ATE230487T1 (en) METHOD FOR EARLY DIAGNOSIS OF CARCINOMAS
EP0907730A4 (en) Haemopoietin receptor and genetic sequences encoding same
DE59609222D1 (en) Amperometric biosensor
ATE180261T1 (en) PROTEINS PRODUCED BY HUMAN LYMPHOCYTES, THE DNA CODING FOR THESE PROTEINS, AND PHARMACEUTICAL AND BIOLOGICAL USES
SE9604815D0 (en) A method or diagnosis
AU7571998A (en) Rapid evaluation of the ratio of biological molecules
MX9606584A (en) Mass-sensitive biosensors.
AU5143099A (en) Protein fragment complementation assays for the detection of biological or drug interactions
ATE205600T1 (en) LEUKOCYTE ADHESION TEST
ATE275268T1 (en) METHOD FOR DIAGNOSIS OF SJÖGREN'S SYNDROME
CA2169121A1 (en) Competitive immunoassay using complexed analyte derivatives
ATE154395T1 (en) MONOCLONAL ANTIBODIES
AU7407096A (en) In vitro methods for determining in vivo thrombotic events
DE3852498T2 (en) ENZYME TEST FOR BIOLOGICAL SUBSTANCES.
AU5801196A (en) Relaxin diagnostic assays and kits, and methods and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase